Month: April 2022

Millicom (Tigo) announces anticipated record date for rights offering and related stoppage of conversion between common shares and SDRs  Luxembourg, April 28, 2022 – In connection with the previously announced rights offering, Millicom International Cellular S.A. (“Millicom”) hereby announces that the record date is expected to be on May 12, 2022 at 5:00 pm New York time for holders of the Company’s common shares and the same date (end of day, Swedish time) for holders of our shares held in the form of Swedish Depositary Receipts (“SDRs”). As announced on November 12, 2021, Millicom intends to raise approximately $750 million by way of a rights offering where its existing shareholders, including holders of SDRs, are granted preferential subscription rights to subscribe for the Company’s common shares, including common shares represented...

Oslo, Norway, April 28, 2022 The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2021 and the report is attached, in addition to the report according to the European Single Electronic Format (ESEF). The Annual Report 2021 is also available on the company’s website www.pcibiotech.com. For further information, please contact:        PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo        Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429        Ronny Skuggedal, CFO, rs@pcibiotech.no, Mobile: +47 940 05 757 About PCI Biotech        PCI Biotech is a biopharmaceutical clinical stage development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI induces triggered endosomal...

Bids, sales, stop-rates and prices are presented in the table below:      ISIN Bid Mill. kr. (nominal) Sale Stop-rate (per cent) Pro-rata Price98 18502 DKT 01/06/22 II 400 0 – – –98 18692 DKT 01/09/22 III 1,600 1,100 -0.535 100 % 100.181698 18775 DKT 01/12/22 IV 0 0 – – –Total 2,000 1,100      The sale will settle 2 May 2022.

Íslandsbanki will publish its first quarter 2022 financial results after market close on 5 May 2022. A webcast will take place on Friday 6 May at 8.30 Reykjavík/GMT, 9.30 London/BST, 10.30 CET Íslandsbanki will host a webcast in English for investors and market participants on Friday 6 May at 8.30 GMT. Birna Einarsdóttir, CEO, and Jón Guðni Ómarsson, CFO, will give an overview of the first quarter financial results and operational highlights. Participant registration is accessible via this link. A recording will be available after the meeting on the Investor Relations website. To participate in the webcast via telephone and in order to be able to ask questions please use the following dial-in details:Iceland: +354 800 74 37Denmark: +45 354 45 577Sweden: +46 8 566 42 651Norway: +47 235 00 243United Kingdom: +44 33 330 00...

Oslo, 28 April 2022: Scatec, a leading renewable energy solutions provider, and its partners have refinanced the non-recourse project debt for six solar power plants in Egypt, with a total capacity of 380 megawatts (MW), through the issuance of a 19-year USD 334.5 million non-recourse Green Project Bond. The refinancing will provide increased leverage, extended tenor, and reduced interest costs which will improve Scatec’s and its project partner’s future cash distributions from the power plants. The Project Bond benefits from a Climate Bond certificate from the Climate Bond Initiative. This innovative climate finance transaction is the first of its kind in Africa and has been distributed to a consortium of development finance institutions, comprising the European Bank for Reconstruction and Development (EBRD), the US International Development...

Active Biotech’s Annual Report 2021 is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. Download as PDF Lund, April 28, 2022 Active Biotech AB (publ) Helén Tuvesson CEO For further information, please contact: Helén Tuvesson, CEO, tel. +46 46 19 21 56, helen.tuvesson@activebiotech.com Hans Kolam, CFO, tel. +46 46 19 20 44, hans.kolam@activebiotech.com This information is information that Active Biotech AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 09.40 a.m. CET on April 28, 2022. About Active BiotechActive Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for...